Search Result

Pathways Recommended:	Anti-infection

Results for "

enteric infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (4) Apoptosis (2) Bacterial (9) Endogenous Metabolite (2) Isotope-Labeled Compounds (2) Parasite (2) Reference Standards (2) RSV (1) SARS-CoV (1)
By Research Areas:	Infection (12) Inflammation/Immunology (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1267

Sulfaguanidine 1 Publications Verification	Bacterial Antibiotic	Infection
Sulfaguanidine is an orally active antimicrobial agent/antibiotic of sulfonamide class. Sulfaguanidine can be used for the research of enteric infections such as bacillary dysentery .

HY-B1267R

Sulfaguanidine (Standard)	Reference Standards Bacterial Antibiotic	Infection
Sulfaguanidine (Standard) is the analytical standard of Sulfaguanidine. This product is intended for research and analytical applications. Sulfaguanidine is an orally active antimicrobial agent/antibiotic of sulfonamide class. Sulfaguanidine can be used for the research of enteric infections such as bacillary dysentery .

HY-B0337S

Sulfadimethoxine-d4 Sulphadimethoxine-d₄	Bacterial	Infection
Sulfadimethoxine-d₄ is a deuterium labeled Sulfadimethoxine (Sulphadimethoxine). Sulfadimethoxine is a sulfonamide antibiotic used to treat many infections including treatment of respiratory, urinary tract, enteric, and soft tissue infections .

HY-B1267S1

Sulfaguanidine-13C6	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Sulfaguanidine- ¹³C₆ is the ¹³C₆ labeled Sulfaguanidine. Sulfaguanidine is an orally active antimicrobial agent/antibiotic of sulfonamide class. Sulfaguanidine can be used for the research of enteric infections such as bacillary dysentery.

HY-W071746

Linolelaidic acid 1 Publications Verification Linoelaidic acid	Endogenous Metabolite Parasite Apoptosis	Infection Inflammation/Immunology
Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections .

HY-121696

Penicillin N Adicillin	Bacterial	Others
Penicillin N (Adicillin) is a penicillin-type compound used to inhibit enteric bacilli infections.

HY-B1267S

Sulfaguanidine-d4	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Sulfaguanidine-d₄ is the deuterium labeled Sulfaguanidine. Sulfaguanidine, belongs to the class of sulfonamide agent, is an orally active antibiotic. Sulfaguanidine can be used for the research of enteric infections such as bacillary dysentery .

HY-W071746R

Linolelaidic acid (Standard) Linoelaidic acid (Standard)	Reference Standards Endogenous Metabolite Parasite Apoptosis	Infection Inflammation/Immunology
Linolelaidic acid (Standard) is the analytical standard of Linolelaidic acid. This product is intended for research and analytical applications. Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections[1][2][3].

HY-169977

CKP-25	SARS-CoV	Infection
CKP-25 is an inhibitor for the interaction between Spike RBD-ACE2, that prevents the virus from entering the host cell, thereby reducing the replication and virus infection. CKP-25 inhibits SARS-CoV-2 with IC₅₀ of 3.5 μM in Vero E6 cell .

HY-P10980

Citrocin	Bacterial	Infection
Citrocin is a potent bacterial RNA polymerase (RNAP) inhibitor. Citrocin shows significant inhibitory activity against Escherichia coli RNAP with an MIC range of 16-125 μM. Citrocin specifically binds to and inhibits RNA polymerase to block bacterial transcription and enters cells mainly through inner membrane protein SbmA. Citrocin is promising for research of Gram-negative bacterial infections, such as enterohemorrhagic E. coli .

HY-171983

RSV-IN-13	RSV	Infection
RSV-IN-13 (compound 24) is a selective RSV fusion protein inhibitor with antiviral activity. RSV-IN-13 has an EC₅₀ of 444.2 nM against RSV A2 strain and a CC₉₀ of 23.7 μM in HepG2 cells. RSV-IN-13 can block the virus from entering host cells. RSV-IN-13 can be used to study RSV infection .

HY-P10970

RT2	Bacterial	Infection
RT2 is a tryptophan-rich cationic amphipathic antibacterial peptide, with main targets including lipopolysaccharide (LPS) on the bacterial surface and intracellular DNA. RT2 binds to bacterial surface LPS, and interacts with cytoplasmic membrane phospholipids, enabling it to rapidly penetrate the bacterial cell membrane and enter the cell, and then bind to components such as DNA in the cytoplasmic membrane, thereby exerting antibacterial effects. RT2 is promising for research of acute and chronic infections caused by planktonic bacteria .

HY-N12323

6′-Galactosyllactose	Others	Inflammation/Immunology
6′-Galactosyllactose is the main oligosaccharide that makes up galactose, a component of human milk. 6′-Galactosyllactose can synthesize human milk oligosaccharides and synthetic galactosyllactose with 3′-Galactosyllactose and 4′-Galactosyllactose, and reduce inflammation in human T84, NCM-460 and H4 cells and intestinal tissues .

HY-P6172

GCO-(GPO)10-GCOG	Bacterial	Infection
GCO-(GPO)10-GCOG is a GPO repeat-containing peptide with a single collagen triple helix structure similar to collagen. The cross-linked triple helix GCO-(GPO)10-GCOG can form a collagen-related peptide (CRP) mimetic that tightly binds to the Yersinia adhesin YadA. YadA mediates the adhesion of the human enteric pathogen Yersinia enterocolitica to collagen and other extracellular matrix components, potentially interfering with host processes mediated by endogenous collagen-binding proteins in vivo. GCO-(GPO)10-GCOG can be used to study YadA-associated infections .

Cat. No.	Product Name

HY-L002

Anti-Infection Compound Library	3,530 compounds
An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents. MCE provides a unique collection of 3,530 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

Anti-Infection Compound Library

3,530 compounds

An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents.

MCE provides a unique collection of 3,530 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

HY-L181

Bioactive Compound Library Max	25,157 compounds
Bioactive small molecules are important sources of lead compounds and effective tools for drug screening. Because the target of active small molecules is clear, it is conducive to the study of mechanism. In addition, due to the large structural differences between the individual active molecules, it is easier to obtain a greater variety of lead compounds. MCE integrates the Bioactive Compound Library (HY-L001) and Novel Bioactive Compound Library (HY-L111) to form the Bioactive Compound Library Max. Bioactive Compound Library Max contains novel active small molecules, molecules that have entered the clinical stage and the market, and small molecules that have been verified by cell experiments or biochemical experiments, which fundamentally expands the number of compound libraries in the library and improves the structural diversity, and is an effective tool to start drug screening and mechanism research. MCE can provide a library of 25,157 mitophagy compounds, which can be used for drug development and mechanism research in cancer, immunity, infection and other hot research fields.

Bioactive Compound Library Max

25,157 compounds

Bioactive small molecules are important sources of lead compounds and effective tools for drug screening. Because the target of active small molecules is clear, it is conducive to the study of mechanism. In addition, due to the large structural differences between the individual active molecules, it is easier to obtain a greater variety of lead compounds.

MCE integrates the Bioactive Compound Library (HY-L001) and Novel Bioactive Compound Library (HY-L111) to form the Bioactive Compound Library Max. Bioactive Compound Library Max contains novel active small molecules, molecules that have entered the clinical stage and the market, and small molecules that have been verified by cell experiments or biochemical experiments, which fundamentally expands the number of compound libraries in the library and improves the structural diversity, and is an effective tool to start drug screening and mechanism research.

MCE can provide a library of 25,157 mitophagy compounds, which can be used for drug development and mechanism research in cancer, immunity, infection and other hot research fields.

Cat. No.	Product Name	Target	Research Area